GOT2

Across TCGA pan-cancer cohorts, GOT2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GOT2 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher GOT2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GOT2 expression acts as an unfavorable survival marker, although some lineages such as COAD and LSCC show a favorable association.

COAD, LUAD, and CCRCC are the cancer types where GOT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	II,III,IV	1.000	0.910	.011	36	view →
LUAD	DFS	Quartile	All	0.491	0.890	.001	21	view →
CCRCC	OS	Quartile	All	0.754	0.961	.014	8	view →
LSCC	OS	Median	II,III,IV	1.000	0.881	.016	4	view →
PDAC	DFS	Tertile	IV	0.225	0.558	.024	3	view →
HNSC	DFS	Median	III,IV	1.000	0.939	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GOT2–COAD (DFS)

Open the COAD breakdown →